Prevention and management of major side effects of targeted agents in breast cancer (Q37785387)

23 August 2017

title

Prevention and management of major side effects of targeted agents in breast cancer (English)

1 reference

23 August 2017

2

Kamal S. Saini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20817545

7 July 2024

author name string

Otto Metzger Filho

1

1 reference

23 August 2017

Ahmad Awada

4

1 reference

23 August 2017

Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME)

5

1 reference

23 August 2017

Hatem A. Azim

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20817545

7 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20817545

7 July 2024

publication date

15 March 2011

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S1040842810001812?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

https://api.elsevier.com/content/article/PII:S1040842810001812?httpAccept=text/plain

7 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Critical Reviews in Oncology Hematology

7 July 2024

published in

1 reference

23 August 2017

volume

84 Suppl 1

1 reference

23 August 2017

page(s)

e79-85

1 reference

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

7 July 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

7 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

7 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Selectivity and therapeutic inhibition of kinases: to be or not to be?

7 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

7 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer

7 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Bre

7 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.

7 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial

7 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

7 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

7 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

7 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy

7 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Cardiac dysfunction in the trastuzumab clinical trials experience

7 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

7 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial

7 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

7 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

7 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Trastuzumab versus lapatinib: the cardiac side of the story

7 July 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells

7 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment

7 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer

7 July 2024

27

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.

7 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Trastuzumab-associated cardiotoxicity

7 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Heart failure with preserved ejection fraction

7 July 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

The evaluation of left ventricular function for patients being considered for, or receiving Trastuzumab (Herceptin) therapy

7 July 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group.

7 July 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

7 July 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

7 July 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management

7 July 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

7 July 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

An open-label expanded access study of lapatinib and capecitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer.

7 July 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

7 July 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

7 July 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Lapatinib-associated toxicity and practical management recommendations

7 July 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Pooled analysis of diarrhea events in patients with cancer treated with lapatinib

7 July 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Mechanisms of cutaneous toxicities to EGFR inhibitors.

7 July 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies

7 July 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

Skin toxicities of targeted therapies.

7 July 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.CRITREVONC.2010.07.014

7 July 2024

Identifiers

1 reference

23 August 2017

1 reference